Cempra Inc. Doses First Patients in Solithromycin (CEM-101) Phase 2 Trial in Uncomplicated Urogenital Gonococcal Infections – Yahoo Finance

The company also intends to utilize its series of proprietary lead compounds from its novel macrolide library for uses such as the treatment of chronic inflammatory diseases, endocrine diseases and gastric motility disorders.  Additional …

Leave a Reply

Your email address will not be published.